Cassava Sciences, Inc.
SAVACassava Sciences, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer's disease. The company is engaged in discovering and developing small molecule drugs aimed at addressing underlying causes of neurodegeneration and cognitive decline. Cassava Sciences is also involved in research to better understand the pathology of Alzheimer’s and to identify potential biomarkers for diagnosis and treatment efficacy.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| December 24, 2012 | $0.75 | 2012-12-13 | 2012-12-17 |
| December 10, 2010 | $2.00 | 2010-12-13 | 2010-12-01 |
Dividends Summary
- Consistent Payer: Cassava Sciences, Inc. has rewarded shareholders with 2 dividend payments over the past 2 years.
- Total Returned Value: Investors who held SAVA shares during this period received a total of $2.75 per share in dividend income.
- Latest Payout: The most recent dividend of $0.75/share was paid 4778 days ago, on December 24, 2012.
- Dividend Growth: Since 2010, the dividend payout has decreased by 62.5%, from $2.00 to $0.75.
Company News
Cassava Sciences announced a definitive agreement to settle consolidated securities class action litigation for $31.25 million, which the company had fully reserved in Q2 2025. The settlement resolves claims from shareholders who purchased company stock between September 2020 and October 2023. The company states this is not an admission of fault ...
Biotechnology company Cassava Sciences announced the appointment of Dawn C. Bir to its Board of Directors, bringing extensive biopharmaceutical executive experience to support the company's clinical development of simufilam for TSC-related epilepsy.
LEQEMBI, an Alzheimer's disease treatment developed by Biogen and Eisai, has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. The Alzheimer's disease market is highly competitive, with numerous companies advancing therapies in the pipeline.
A securities class action lawsuit has been filed against Cassava Sciences, Inc. (SAVA) on behalf of investors who purchased or acquired Cassava securities between February 7, 2024, and November 24, 2024. The lawsuit alleges that Cassava misrepresented the ability of its drug, simufilam, to abate the progression of Alzheimer's Disease.
Cassava Sciences, Inc. (SAVA) is facing a securities class action lawsuit after its leading drug candidate, simufilam, failed to meet the pre-specified endpoints in a Phase 3 clinical trial for Alzheimer's disease.
